ABLD.PA AbL Diagnostics SA

Healthcare Health Care Technology Euronext Paris
2.44 EUR
Close of Nov 8, 2026
2.03 4.79
Market cap
EUR 39.2M
P/E
20.3x
P/B
5.53x
ROE
12.9%
Dividend yield
4.51%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ABLD.PA undervalued?

Graham number
Price2.44
Graham value1.09
Premium123.5%

ABLD.PA trades 123.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AbL Diagnostics SA fundamental analysis

No fundamental analysis for AbL Diagnostics SA yet.

AbL Diagnostics SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AbL Diagnostics SA

ABL Texcell Diagnostics SA provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA, hepatitis-B Virus (HBV), cytomegalovirus (CMV), herpes simplex virus (HSV), BK …

Full company profile